[go: up one dir, main page]

MX2009008509A - Compuesto de anillo puenteado-aza. - Google Patents

Compuesto de anillo puenteado-aza.

Info

Publication number
MX2009008509A
MX2009008509A MX2009008509A MX2009008509A MX2009008509A MX 2009008509 A MX2009008509 A MX 2009008509A MX 2009008509 A MX2009008509 A MX 2009008509A MX 2009008509 A MX2009008509 A MX 2009008509A MX 2009008509 A MX2009008509 A MX 2009008509A
Authority
MX
Mexico
Prior art keywords
aza
bridged
muscarinic
receptor
antagonistic activity
Prior art date
Application number
MX2009008509A
Other languages
English (en)
Inventor
Toru Kontani
Hisao Hamaguchi
Hiroshi Nagata
Shinya Nagashima
Yuji Matsushima
Tadatsura Koshika
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2009008509A publication Critical patent/MX2009008509A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona un compuesto que tiene una actividad antagónica en el receptor M3 muscarínico, y por consiguiente es útil como un ingrediente activo de un agente profiláctico y/o terapéutico para una enfermedad inflamatoria tal como enfermedad pulmonar obstructiva crónica (COPD) y asma. Se realizó un estudio en un compuesto que tiene una actividad antagónica en el enlace de un receptor M3 muscarínico. Como consecuencia, se descubrió que un compuesto de anillo puenteado-aza representado por la fórmula (1) o una sal del mismo, tiene una actividad antagónica en el enlace de un receptor M3 muscarínico. El compuesto de anillo puenteado-aza tiene una actividad antagónica en el enlace de un receptor M3 muscarínico y por consiguiente se puede utilizar como un agente profiláctico y/o terapéutico para una enfermedad inflamatoria tal como enfermedad pulmonar obstructiva crónica (COPD) y asma, (1) en donde R1 representa -H o un C1-6 alquilo; R2 representa un anillo puenteado-aza seleccionado del grupo que consiste en los anillos representados por las fórmulas (a), (b), (c) y (d) que se encuentran más adelante; y R3 representa un tienilo, un fenilo, un piridilo, un pirazinilo, un tiazolilo o un pirazolilo.
MX2009008509A 2007-02-09 2008-02-08 Compuesto de anillo puenteado-aza. MX2009008509A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007030963 2007-02-09
PCT/JP2008/052189 WO2008096870A1 (ja) 2007-02-09 2008-02-08 アザ架橋環化合物

Publications (1)

Publication Number Publication Date
MX2009008509A true MX2009008509A (es) 2009-08-20

Family

ID=39681769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008509A MX2009008509A (es) 2007-02-09 2008-02-08 Compuesto de anillo puenteado-aza.

Country Status (12)

Country Link
US (1) US8367696B2 (es)
EP (1) EP2119716A4 (es)
JP (1) JP5293192B2 (es)
KR (1) KR20090107567A (es)
CN (1) CN101605784B (es)
AU (1) AU2008212171A1 (es)
BR (1) BRPI0806972A2 (es)
CA (1) CA2678193A1 (es)
IL (1) IL200152A0 (es)
MX (1) MX2009008509A (es)
RU (1) RU2441868C2 (es)
WO (1) WO2008096870A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
ES2363998T3 (es) * 2007-03-23 2011-08-22 Abbott Laboratories Derivados ester y carbamato de azaadamantano y métodos de uso de los mismos.
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives
JOP20130273B1 (ar) * 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
WO2014051055A1 (ja) * 2012-09-28 2014-04-03 東レ株式会社 キヌクリジンウレア誘導体及びその医薬用途
AU2014292722B2 (en) * 2013-07-13 2017-03-09 Beijing Showby Pharmaceutical Co., Ltd. Quinine compounds, and optical isomers, preparation method and medical use thereof
KR101538846B1 (ko) * 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법
WO2017114377A1 (zh) * 2015-12-29 2017-07-06 四川海思科制药有限公司 一种苯基杂环衍生物及其在医药上的用途
PH12019500380B1 (en) * 2016-08-26 2024-04-17 Dong A St Co Ltd Novel salt of (r)-(1-methylpyrrolidine-3-yl)methyl(3`-chloro-4`fluoro-[1,1`-biphenyl]-2-yl)carbamate and a crystal form thereof
KR102239776B1 (ko) * 2016-08-26 2021-04-13 동아에스티 주식회사 (r)-(1-메틸피롤리딘-3-일)메틸(3'-클로로-4'-플루오로-[1,1'-비페닐]-2-일)카바메이트의 신규염 및 이의 결정형
WO2019096226A1 (en) 2017-11-16 2019-05-23 Chengdu Easton Biopharmaceuticals Co., Ltd. Pasylated vegfr/pdgfr fusion proteins and their use in therapy
WO2019110521A1 (en) 2017-12-04 2019-06-13 Friedrich-Alexander-Universität Erlangen-Nürnberg Fluorophenyl substituted muscarinic receptor ligands with selectivity for m3 over m2
CN115427038A (zh) 2020-02-03 2022-12-02 建新公司 治疗与溶酶体贮积病相关的神经系统症状的方法
AU2021311131A1 (en) 2020-07-24 2023-03-23 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ224237A (en) 1987-04-15 1991-04-26 Beecham Group Plc Bicyclic compounds (n bridged compounds)
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
CN1140447A (zh) * 1994-02-10 1997-01-15 山之内制药株式会社 新的氨基甲酸酯衍生物及其药物组合物
KR970701174A (ko) 1994-02-10 1997-03-17 오노다 마사요시 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
WO1995024399A1 (en) 1994-03-11 1995-09-14 Yamanouchi Pharmaceutical Co., Ltd. 5-ht3 receptor agonist, novel thiazole derivative, and intermediate therefor
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
UY25225A1 (es) 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
US6916828B2 (en) 2000-06-27 2005-07-12 Laboratorios S.A.L.V.A.T., S.A. Carbamates derivatived from arylakylamines
AU2002228015B2 (en) 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
PT1353919E (pt) 2000-12-28 2006-11-30 Almirall Prodesfarma Ag Novos derivados de quinuclidina e composições medicinais contendo os mesmos
JP2003267977A (ja) * 2002-03-14 2003-09-25 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
DE10255040A1 (de) 2002-11-26 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbaminsäureester mit anticholinerger Wirksamkeit
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2006005057A2 (en) 2004-06-30 2006-01-12 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
EP1904446A2 (en) 2005-07-11 2008-04-02 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
WO2008041184A2 (en) 2006-10-03 2008-04-10 Ranbaxy Laboratories Limited Muscarinic receptor antagonists

Also Published As

Publication number Publication date
IL200152A0 (en) 2010-04-15
CN101605784B (zh) 2013-04-10
US20100105658A1 (en) 2010-04-29
JP5293192B2 (ja) 2013-09-18
BRPI0806972A2 (pt) 2014-04-08
EP2119716A4 (en) 2011-06-01
AU2008212171A1 (en) 2008-08-14
US8367696B2 (en) 2013-02-05
KR20090107567A (ko) 2009-10-13
RU2441868C2 (ru) 2012-02-10
RU2009133781A (ru) 2011-03-20
EP2119716A1 (en) 2009-11-18
WO2008096870A1 (ja) 2008-08-14
CN101605784A (zh) 2009-12-16
JPWO2008096870A1 (ja) 2010-05-27
CA2678193A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
MX2009008509A (es) Compuesto de anillo puenteado-aza.
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
MX353957B (es) Carboxamidas heterociclicas fungicidas.
JP2013501720A5 (es)
PH12012502572A1 (en) Novel nicotinamide derivative or salt thereof
WO2013010946A3 (en) Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests i
WO2009010660A3 (fr) Indazoles substitues, leur preparation et leur utilisation en therapeutique
TNSN08104A1 (en) Pyrimidine amide compounds as pgds inhibitors
TN2012000033A1 (en) Mixtures of mesoionic pesticides
TNSN07164A1 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
WO2008108380A3 (en) Pyrrole compounds
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
JP2010504286A5 (es)
MX2015013348A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
MX2009007482A (es) Agentes antiparasitarios.
MX2014003419A (es) Composicion de control de fitoenfermedades y su uso.
MY169179A (en) Novel piperidine compound or salt thereof
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
JO3098B1 (ar) مركبات داي فينيل- بيرازول بيريدين وطريقة تحضيرها واستخدامها كمعدلات المستقبل النووي not
IN2014DN01993A (es)
PH12014500775A1 (en) Ethynyl derivatives as mglur5 allosteric modulators
MX2015014406A (es) Carboxamidas fungicidas.
WO2009020137A1 (ja) アミノピラゾールアミド誘導体
JP2016500653A5 (es)
WO2008141469A3 (en) Butone derivatives useful as cooling agents

Legal Events

Date Code Title Description
FA Abandonment or withdrawal